Aspargo Laboratories announced it raised $290,000 in an initial filing from an offering of $15 Million

Company

Location

About

Aspargo Labs, Inc. is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. Aspargo’s initial focus is a liquid oral suspension formulation of sildenafil for the treatment of ED, which the Company markets in Europe and the United Kingdom.